Investments
4Portfolio Exits
1Partners & Customers
10About Chiesi Farmaceutici
Chiesi Farmaceutici is an international research-focused pharmaceutical company that researches, develops, and markets drugs in the respiratory therapeutics, neonatology, specialist medicine, and rare diseases areas.
Chiesi Farmaceutici Headquarter Location
Via Palermo, 26/A
Parma, 43122,
Italy
+39 0521 2791
Latest Chiesi Farmaceutici News
Jan 25, 2022
The US subsidiary of Italian drugmaker Chiesi Farmaceutici has announced that a post hoc analysis of the CHAMPION PHOENIX clinical trial that evaluated treatment of Kengreal (cangrelor) in patients undergoing percutaneous coronary intervention (PCI) was published in Circulation: Cardiovascular Interventions. The analysis found that the majority of ischemic events occurred early in PCI, and Kengreal treatment significantly reduced these events in the first two hours post-randomization compared to clopidogrel, the standard of care. “These results demonstrate the importance of potent platelet inhibition during this critical window of treatment,” said Martin Marciniak, vice president and head of US medical affairs at Chiesi. “We are thankful for the contributions of everyone who participated in this valuable analysis, and we’re committed to supporting advancements in interventional cardiology to improve care for cardiac patients,” he added.
Chiesi Farmaceutici Investments
4 Investments
Chiesi Farmaceutici has made 4 investments. Their latest investment was in Cyclica as part of their Series B on June 6, 2020.
Chiesi Farmaceutici Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/24/2020 | Series B | Cyclica | $17M | Yes | 4 | |
9/25/2018 | Series B - II | |||||
7/10/2013 | Project Finance | |||||
7/10/2013 | Series B |
Date | 6/24/2020 | 9/25/2018 | 7/10/2013 | 7/10/2013 |
|---|---|---|---|---|
Round | Series B | Series B - II | Project Finance | Series B |
Company | Cyclica | |||
Amount | $17M | |||
New? | Yes | |||
Co-Investors | ||||
Sources | 4 |
Chiesi Farmaceutici Portfolio Exits
1 Portfolio Exit
Chiesi Farmaceutici has 1 portfolio exit. Their latest portfolio exit was uniQure on February 05, 2014.
Chiesi Farmaceutici Acquisitions
4 Acquisitions
Chiesi Farmaceutici acquired 4 companies. Their latest acquisition was Smart Pharma on September 17, 2020.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/17/2020 | Seed / Angel | $0.4M | Acquired | 2 | ||
11/21/2016 | Debt | |||||
2/4/2014 | Other Venture Capital | |||||
8/26/2013 | Grant |
Date | 9/17/2020 | 11/21/2016 | 2/4/2014 | 8/26/2013 |
|---|---|---|---|---|
Investment Stage | Seed / Angel | Debt | Other Venture Capital | Grant |
Companies | ||||
Valuation | ||||
Total Funding | $0.4M | |||
Note | Acquired | |||
Sources | 2 |
Chiesi Farmaceutici Partners & Customers
10 Partners and customers
Chiesi Farmaceutici has 10 strategic partners and customers. Chiesi Farmaceutici recently partnered with Kaia Health on November 11, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
11/30/2020 | Client | Kaia Health | United States | Kaia Health teams with Chiesi Group to commercialise COPD app in Europe Konstantin Mehl , Kaia Health founder and president , said : `` Our strategic partnership with Chiesi , a growing global company with an established European commercial presence , brings a wealth of experience in navigating the respiratory health landscape in Europe , while expanding patient access to evidence-based , digital physical pulmonary rehabilitation . '' | 6 |
9/1/2020 | Vendor | JAGGAER | United States | Chiesi Group and JAGGAER Drive Strategic Supplier Management and Procurement Excellence `` JAGGAER has been a terrific partner , helping us exceed B Corp certification standards and build transparency , efficiency , and agility in our approach with defined processes , clear ownership and accountability , management over exceptions , structured information sharing , and more . '' | 2 |
7/6/2020 | Licensor | Bioasis Technologies | United States | Bioasis and Chiesi announce licensing agreement - BioCT Bioasis Technologies and Chiesi announce licensing agreement . | 1 |
6/29/2020 | Licensor | ||||
12/10/2018 | Partner |
Date | 11/30/2020 | 9/1/2020 | 7/6/2020 | 6/29/2020 | 12/10/2018 |
|---|---|---|---|---|---|
Type | Client | Vendor | Licensor | Licensor | Partner |
Business Partner | Kaia Health | JAGGAER | Bioasis Technologies | ||
Country | United States | United States | United States | ||
News Snippet | Kaia Health teams with Chiesi Group to commercialise COPD app in Europe Konstantin Mehl , Kaia Health founder and president , said : `` Our strategic partnership with Chiesi , a growing global company with an established European commercial presence , brings a wealth of experience in navigating the respiratory health landscape in Europe , while expanding patient access to evidence-based , digital physical pulmonary rehabilitation . '' | Chiesi Group and JAGGAER Drive Strategic Supplier Management and Procurement Excellence `` JAGGAER has been a terrific partner , helping us exceed B Corp certification standards and build transparency , efficiency , and agility in our approach with defined processes , clear ownership and accountability , management over exceptions , structured information sharing , and more . '' | Bioasis and Chiesi announce licensing agreement - BioCT Bioasis Technologies and Chiesi announce licensing agreement . | ||
Sources | 6 | 2 | 1 |